官方服务：
资源简介：
Supplementary file to article titled: Mapping the time-course and associated factors of placebo response to systemic immunomodulatory treatments for atopic dermatitis
应用场景：
创建时间：
2025-08-21
相关数据集
Supplementary Material for: The Effects of Mucopolysaccharide Polysulfate on Steroid-Induced Tight Junction Barrier Dysfunction in Human Epidermal Keratinocytes and a 3D Skin Model
Introduction: The long-term use of topical corticosteroids (TCS) is associated with side effects such as skin atrophy and barrier deterioration. Moisturizers, such as mucopolysaccharide polysulfate (M
NIAID Data Ecosystem70
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial
Author video for the article: Paller AS, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, do
NIAID Data Ecosystem20
Supplementary Material for: Efficacy and Safety of Upadacitinib Versus Dupilumab Treatment for Moderate to Severe Atopic Dermatitis in Four Body Regions: Analysis From the Heads-Up Study
Introduction: Upadacitinib has demonstrated high and rapid rates of efficacy in adolescent and adult patients with moderate-to-severe atopic dermatitis (AD) as assessed by the Eczema Area and Severity
Figshare2024-10-29 更新20
Full-text articles assessed for eligibility.
Background The newly approved biologics and Janus kinase inhibitors (JAKi) for pediatric atopic dermatitis (AD) offer additional options for clinical treatment. However, the efficacy and safety differ
NIAID Data Ecosystem50
Efficacy and safety of Ivarmacitinib in moderate-to-severe atopic dermatitis patients with or without previous systemic treatments: a post-hoc analysis of a phase III trial
Prior exposure to systemic treatments may affect treatment outcomes in moderate-to-severe atopic dermatitis (AD). This study aimed to explore the efficacy and safety of Ivarmacitinib (SHR0302) in mode
DataCite Commons2025-12-16 更新20
